This study has 8 locations in USA - 11 Dec `20Evaluation of AMG 714 for Vitiligo (REVEAL)

Official title: Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

The AMG 714 for Vitiligo (REVEAL Trial), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is a Phase 2 clinical study evaluating the efficacy and safety of AMG 714, an anti-IL-15 monoclonal antibody, in adults with vitiligo. The trial aims to determine if AMG 714, combined with narrowband ultraviolet B (nbUVB) phototherapy, can effectively restore skin pigmentation by modulating the immune response responsible for melanocyte destruction.

This is an active study which is not recruiting new patients.

 

Start date: 2020-12-11

Completion date: 2025-05-30

Contact: Brett A. King, MD, PhD

Tel.:

Email:

Link: https://clinicaltrials.gov/study/NCT04338581

Clinical Trials Alerts

Sign up and be the first to know when new trials are starting nearby.



FAQOther Questions

  • What causes vitiligo?

    Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...

  • How can I explain vitiligo to my children?

    Vitiligo can be confusing for children because it doesn’t resemble an "illness" in the typical sense. Choosing the right way to explain it depends on your child’s age and maturi...

  • Is vitiligo contagious?

    Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo ...